ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Large accelerated filer
|
☐
|
|
☑
|
||
Non-accelerated filer
|
☐
|
Smaller reporting company
|
|
||
Emerging growth company
|
|
Page No.
|
||
PART I
|
||
ITEM 1.
|
5
|
|
ITEM 1A.
|
17
|
|
ITEM 1B.
|
36
|
|
ITEM 1C.
|
36
|
|
ITEM 2.
|
37
|
|
ITEM 3.
|
37
|
|
ITEM 4.
|
37
|
|
PART II
|
||
ITEM 5.
|
39
|
|
ITEM 6.
|
40
|
|
ITEM 7.
|
41
|
|
ITEM 7A.
|
57
|
|
ITEM 8.
|
58
|
|
ITEM 9.
|
96
|
|
ITEM 9A.
|
96
|
|
ITEM 9B.
|
98
|
|
ITEM 9C.
|
98
|
|
PART III
|
||
ITEM 10.
|
99
|
|
ITEM 11.
|
99
|
|
ITEM 12.
|
99
|
|
ITEM 13.
|
99
|
|
ITEM 14.
|
99
|
|
PART IV
|
||
ITEM 15.
|
100
|
|
ITEM 16.
|
103
|
|
104
|
• |
Zig-Zag® is the #1 premium and #1 overall rolling paper brand in the U.S., with
significant distribution in Canada as well. Zig-Zag® is also the #1 MYO cigar wrap brand in the U.S., as measured
by MSAi.1 We acquired North American rolling papers distribution rights for Zig-Zag® in 1997. More importantly, we own the Zig-Zag® tobacco
trademark in the U.S. which we leverage for our MYO cigar wraps product. Approximately 41% of our total 2023 Zig-Zag® branded net sales are under our own Zig-Zag® marks rather than those we license from
RTI under the Distribution and Licensing Agreements described below.
|
• |
Stoker’s® is among the fastest growing MST brands in the industry and is the #1
loose-leaf chewing tobacco brand.1 We manufacture Stoker’s® MST using only 100% American Leaf, utilizing a proprietary process to produce what we believe is a superior product.
|
• |
In 2009, we extended the Zig-Zag® tobacco brand into the MYO cigar wraps market and
captured a 50% market share within the first two years. We are now the market share leader for MYO cigar wraps with approximately a 55% share of the cigar wraps category and 76% of the share of the HTL cigar wraps sub-category. 1 We believe our success was driven by the Zig-Zag® tobacco branding, which we feel is widely understood by consumers to represent a favorable, customizable experience ideally suited to MYO products. In late 2021, we extended our Zig-Zag® MYO cigar wraps offering with entries into the growing hemp wraps and natural leaf wraps markets.
|
• |
We extended the Zig-Zag® brand into hemp rolling papers in 2018 and followed that
with the launch of paper cones in 2019 with both products quickly establishing leading positions in their respective categories.
|
• |
We leveraged the proud legacy and value of the Stoker’s® brand to introduce a 12
oz. MST tub, a size that was not offered by any other market participant at the time of introduction. Stoker’s® MST
has been among the fastest growing moist snuff brands in the industry in terms of pounds sold. While competitors have since introduced larger format tub packaging, the early entry and differentiation of the Stoker’s® product have firmly established us as the market leader with over 55% of the tub market as of 2023. In 2015,
we introduced Stoker’s® MST in 1.2 oz. cans to further expand retail penetration, particularly
in convenience stores. In 2023, we expanded our FRĒ® white nicotine pouches into the market with a broader rollout planned in 2024.
|
• |
We have also had success in acquiring, partnering with, and integrating new products and product lines, including:
|
• |
Cigarillos, with the acquisition of Unitabac;
|
• |
Lighters, with exclusive distribution of Clipper lighters in the U.S. and Canada; and
|
• |
Liquid nicotine, with the acquisition of Vapor Beast and International Vapor Group, providing us with both B2B and B2C capabilities that we are able to leverage with our other product lines to reach new
retail outlets and consumers.
|
December 31,
2023
|
December 31,
2022
|
|||||||
Raw materials and work in process
|
$
|
5,201
|
$
|
7,283
|
||||
Leaf tobacco
|
34,894
|
43,468
|
||||||
Finished goods - Zig-Zag Products
|
41,783
|
42,279
|
||||||
Finished goods - Stoker’s Products
|
8,090
|
9,667
|
||||||
Finished goods - Creative Distribution Solutions
|
7,281
|
15,431
|
||||||
Other
|
1,711
|
1,787
|
||||||
Inventories
|
$
|
98,960
|
$
|
119,915
|
• |
The Environmental Committee provides a platform to enhance and track the progress of our environmental practices within our business units. The committee is charged with recommending, implementing, and
monitoring best practices in the areas of carbon emissions, waste, water, and biodiversity within our business units. In 2023, the Company continued to make substantial investments around reducing energy consumption and environmental
waste in our manufacturing operations. Additionally, we have reduced our total mileage through innovative dispatch and scheduling procedures.
|
• |
The Social Committee provides a platform to achieve the objective of being the employer of choice. The committee is charged with recommending and implementing best practices in the areas of health and
safety, DE&I, Talent Development and Retention, and Community Engagement.
|
• |
The Policies Committee provides a platform to review our governance practices and implement new or updated policies as our needs change. The committee is charged with recommending and implementing
appropriate best practices in the areas of business ethics, political engagement, supply chain processes, and cybersecurity. The committee additionally is charged with recommending and implementing best practices in the areas of public
health, responsible marketing, and youth access prevention. In 2023, the Policies Committee developed several new policies, particularly aimed at cybersecurity, and held training sessions with our marketing teams related to prevention of
youth appeal.
|
• |
declining sales of tobacco products, and expected continuing decline of sales in the tobacco industry overall;
|
• |
our dependence on a small number of third-party suppliers and producers;
|
• |
the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption, as well as other supply chain concerns, including delays in
product shipments and increases in freight cost;
|
• |
the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted;
|
• |
failure to maintain consumer brand recognition and loyalty of our customers;
|
• |
our reliance on relationships with several large retailers and national chains for distribution of our products;
|
• |
intense competition and our ability to compete effectively;
|
• |
competition from illicit sources and the damage caused by illicit products to our brand equity;
|
• |
contamination of our tobacco supply or products;
|
• |
uncertainty and continued evolution of the markets for our products;
|
• |
complications with the design or implementation of our new enterprise resource planning system could adversely impact our business and operations;
|
• |
substantial and increasing regulation and changes in FDA enforcement priorities;
|
• |
regulation or marketing denials of our products by the FDA, which has broad regulatory powers;
|
• |
many of our products contain nicotine, which is considered to be a highly addictive substance;
|
• |
requirement to maintain compliance with master settlement agreement escrow account;
|
• |
possible significant increases in federal, state and local municipal tobacco- and nicotine-related taxes;
|
• |
our products are marketed pursuant to a policy of FDA enforcement priorities which could change, and our products could become subject to increased regulatory burdens by the FDA;
|
• |
our products are subject to developing and unpredictable regulation, such as court actions that impact obligations;
|
• |
increase in state and local regulation of our products has been proposed or enacted;
|
• |
increase in tax of our products could adversely affect our business;
|
• |
sensitivity of end-customers to increased sales taxes and economic conditions, including as a result of inflation and other declines in purchasing power;
|
• |
possible increasing international control and regulation;
|
• |
failure to comply with environmental, health and safety regulations;
|
• |
imposition of significant tariffs on imports into the U.S.;
|
• |
the scientific community’s lack of information regarding the long-term health effects of certain substances contained in some of our products;
|
• |
significant product liability litigation;
|
• |
our amount of indebtedness;
|
• |
the terms of our indebtedness, which may restrict our current and future operations;
|
• |
our ability to establish and maintain effective internal controls over financial reporting;
|
• |
identification of material weaknesses in our internal control over financial reporting, which, if not remediated appropriately or timely, could result in loss of investor confidence and adversely impact our
stock price;
|
• |
our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or merger proposals, which may adversely affect the market price
of our common stock;
|
• |
our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors. These restrictions may affect the liquidity of our common stock and may
result in Restricted Investors (as defined in our Certificate of Incorporation) being required to sell or redeem their shares at a loss or relinquish their voting, dividend and distribution rights;
|
• |
future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of equity or convertible securities may dilute your ownership in
us;
|
• |
we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock;
|
• |
our business may be damaged by events outside of our or our suppliers’ control, such as the impact of epidemics (e.g., coronavirus), political upheavals, or natural disasters;
|
• |
adverse impact of climate change;
|
• |
our reliance on information technology;
|
• |
cybersecurity and privacy breaches, which have increased in part due to artificial intelligence;
|
• |
failure to manage our growth;
|
• |
failure to successfully integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions;
|
• |
fluctuations in our results;
|
• |
exchange rate fluctuations;
|
• |
adverse U.S. and global economic conditions;
|
• |
departure of key management personnel or our inability to attract and retain talent;
|
• |
infringement on or misappropriation of our intellectual property;
|
• |
third-party claims that we infringe on their intellectual property; and
|
• |
failure to meet expectations relating to environmental, social and governance factors
|
• |
the levying of substantial and increasing tax and duty charges;
|
• |
restrictions or bans on advertising, marketing and sponsorship;
|
• |
the display of larger health warnings, graphic health warnings and other labeling requirements;
|
• |
restrictions on packaging design, including the use of colors and generic packaging;
|
• |
restrictions or bans on the display of tobacco product packaging at the point of sale, and restrictions or bans on cigarette vending machines;
|
• |
requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents levels;
|
• |
requirements regarding testing, disclosure and use of tobacco product ingredients;
|
• |
increased restrictions on smoking in public and workplaces and, in some instances, in private places and outdoors;
|
• |
elimination of duty-free allowances for travelers; and
|
• |
encouraging litigation against tobacco companies.
|
• |
obtain necessary additional financing for working capital, capital expenditures or other purposes in the future;
|
• |
plan for, or react to, changes in our business and the industries in which we operate;
|
• |
make future acquisitions or pursue other business opportunities;
|
• |
react in an extended economic downturn;
|
• |
pay dividends; and
|
• |
repurchase stock.
|
• |
incur additional debt, disqualified stock and preferred stock;
|
• |
pay dividends and make other restricted payments;
|
• |
create liens;
|
• |
make investments and acquisitions;
|
• |
engage in sales of assets and subsidiary stock;
|
• |
enter into sale-leaseback transactions;
|
• |
enter into transactions with affiliates; and
|
• |
transfer all or substantially all of our assets or enter into merger or consolidation transactions.
|
• |
our reputation may be adversely affected and our business and operating results could be harmed;
|
• |
the market price of our stock could decline;
|
• |
we could fail to meet our financial reporting obligations; and
|
• |
we could be subject to litigation and/or investigations or sanctions by the SEC, the New York Stock Exchange or other regulatory authorities.
|
• |
limitations on the removal of directors;
|
• |
limitations on the ability of our stockholders to call special meetings;
|
• |
limitations on stockholder action by written consent;
|
• |
establishing advance notice provisions for stockholder proposals and nominations for elections to the board of directors to be acted upon at meetings of stockholders; and
|
• |
limitations on the ability of our stockholders to fill vacant directorships or amend the number of directors constituting our board of directors.
|
• |
difficulties integrating personnel from acquired entities and other corporate cultures into our business;
|
• |
difficulties integrating information systems;
|
• |
the potential loss of key employees of acquired companies;
|
• |
the assumption of liabilities and exposure to undisclosed or unknown liabilities of acquired companies; or
|
• |
the diversion of management attention from existing operations
|
Brand
|
Product
|
TPB Segment
|
Market Share(1)
|
Category Rank(1)
|
||
Zig-Zag®
|
Cigarette Papers
|
Zig-Zag Products
|
34.4%
|
#1 premium, #1 overall
|
||
Zig-Zag®
|
MYO Cigar Wraps
|
Zig-Zag Products
|
55.1%
|
#1 overall
|
||
Stoker’s®
|
Moist Snuff
|
Stoker’s Products
|
6.9%
|
#3 discount, #6 overall
|
||
Stoker’s®
|
Chewing Tobacco
|
Stoker’s Products
|
30.5%
|
#1 discount, #1 overall
|
(1) |
Market share and category rank data for all products are derived from MSAi data 2023 52 weeks ended 12/30/23.
|
• |
Our ability to further penetrate markets with our existing products;
|
• |
Our ability to introduce new products and product lines that complement our core business;
|
• |
Decreasing interest in some tobacco products among consumers;
|
• |
Price sensitivity in our end-markets;
|
• |
Marketing and promotional initiatives, which cause variability in our results;
|
• |
Cost related to increasing regulation of promotional and advertising activities;
|
• |
General economic conditions, including consumer access to disposable income and other conditions affecting purchasing power such as inflation and the interest rate environment;
|
• |
Labor and production costs;
|
• |
Cost of complying with regulation, including the “deeming regulation”;
|
• |
Increasing and unpredictable regulation and/or marketing order decisions impacting Creative Distribution Solutions products;
|
• |
Counterfeit and other illegal products in our end-markets;
|
• |
Currency fluctuations;
|
• |
Our ability to identify attractive acquisition opportunities; and
|
• |
Our ability to successfully integrate acquisitions.
|
• |
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date.
|
• |
Level 2 – Inputs to the valuation methodology include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets;
inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
|
• |
Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
|
For the year ended December 31,
|
||||||||||||||||||||
2023
|
2022
|
% Change
|
2021
|
% Change
|
||||||||||||||||
Consolidated Results of Operations Data:
|
||||||||||||||||||||
Net sales
|
||||||||||||||||||||
Zig-Zag products
|
$
|
180,455
|
$
|
190,403
|
-5.2
|
%
|
$
|
176,491
|
7.9
|
%
|
||||||||||
Stoker’s products
|
144,609
|
130,826
|
10.5
|
%
|
124,280
|
5.3
|
%
|
|||||||||||||
Total Zig-Zag and Stoker’s products
|
325,064
|
321,229
|
1.2
|
%
|
300,771
|
6.8
|
%
|
|||||||||||||
Creative Distribution Solutions
|
80,329
|
93,784
|
-14.3
|
%
|
144,700
|
-35.2
|
%
|
|||||||||||||
Total net sales
|
405,393
|
415,013
|
-2.3
|
%
|
445,471
|
-6.8
|
%
|
|||||||||||||
Cost of sales
|
202,152
|
209,475
|
-3.5
|
%
|
227,637
|
-8.0
|
%
|
|||||||||||||
Gross profit
|
||||||||||||||||||||
Zig-Zag products
|
101,055
|
106,576
|
-5.2
|
%
|
102,739
|
3.7
|
%
|
|||||||||||||
Stoker’s products
|
81,887
|
71,254
|
14.9
|
%
|
68,084
|
4.7
|
%
|
|||||||||||||
Total Zig-Zag and Stoker’s products
|
182,942
|
177,830
|
2.9
|
%
|
170,823
|
4.1
|
%
|
|||||||||||||
Creative Distribution Solutions
|
20,299
|
27,708
|
-26.7
|
%
|
47,011
|
-41.1
|
%
|
|||||||||||||
Total gross profit
|
203,241
|
205,538
|
-1.1
|
%
|
217,834
|
-5.6
|
%
|
|||||||||||||
|
||||||||||||||||||||
Selling, general, and administrative expenses
|
125,009
|
130,024
|
-3.9
|
%
|
127,513
|
2.0
|
%
|
|||||||||||||
Other operating income, net
|
(4,345
|
)
|
–
|
NM
|
–
|
NM
|
||||||||||||||
Operating income
|
82,577
|
75,514
|
9.4
|
%
|
90,321
|
-16.4
|
%
|
|||||||||||||
Interest expense, net
|
14,645
|
19,524
|
-25.0
|
%
|
20,500
|
-4.8
|
%
|
|||||||||||||
Investment loss
|
11,914
|
13,303
|
-10.4
|
%
|
6,673
|
99.4
|
%
|
|||||||||||||
Other income
|
(4,000
|
)
|
–
|
NM
|
–
|
NM
|
||||||||||||||
Goodwill and intangible impairment loss
|
–
|
27,566
|
NM
|
–
|
NM
|
|||||||||||||||
Gain on extinguishment of debt
|
(1,664
|
)
|
(885
|
)
|
88.0
|
%
|
(2,154
|
)
|
-58.9
|
%
|
||||||||||
Income before income taxes
|
61,682
|
16,006
|
285.4
|
%
|
65,302
|
-75.5
|
%
|
|||||||||||||
Income tax expense
|
23,901
|
4,849
|
392.9
|
%
|
14,040
|
-65.5
|
%
|
|||||||||||||
Consolidated net income
|
37,781
|
11,157
|
238.6
|
%
|
51,262
|
-78.2
|
%
|
|||||||||||||
Net loss attributable to non-controlling interest
|
(681
|
)
|
(484
|
)
|
40.7
|
%
|
(797
|
)
|
-39.3
|
%
|
||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
38,462
|
$
|
11,641
|
230.4
|
%
|
$
|
52,059
|
-77.6
|
%
|
(in thousands)
|
Years ended December 31,
|
|||||||||||
2023
|
2022
|
2021
|
||||||||||
Consolidated net income
|
$
|
38,462
|
$
|
11,641
|
$
|
52,059
|
||||||
Add:
|
||||||||||||
Interest expense, net
|
14,645
|
19,524
|
20,500
|
|||||||||
Gain on extinguishment of debt
|
(1,664
|
)
|
(885
|
)
|
(2,154
|
)
|
||||||
Income tax expense
|
23,901
|
4,849
|
14,040
|
|||||||||
Depreciation expense
|
3,121
|
3,388
|
3,105
|
|||||||||
Amortization expense
|
3,237
|
1,911
|
1,907
|
|||||||||
EBITDA
|
$
|
81,702
|
$
|
40,428
|
$
|
89,457
|
||||||
Components of Adjusted EBITDA
|
||||||||||||
Corporate and CDS restructuring (a)
|
389
|
3,444
|
1,026
|
|||||||||
ERP/CRM (b)
|
552
|
1,962
|
–
|
|||||||||
Stock options, restricted stock, and incentives expense (c)
|
6,561
|
5,273
|
7,557
|
|||||||||
Transactional expenses and strategic initiatives (d)
|
165
|
801
|
1,267
|
|||||||||
FDA PMTA (e)
|
2,098
|
4,554
|
1,668
|
|||||||||
Non-cash asset impairment (f)
|
12,177
|
41,136
|
7,100
|
|||||||||
FET Refund (g)
|
(4,345
|
)
|
–
|
–
|
||||||||
Legal settlement (h)
|
(4,000
|
)
|
–
|
–
|
||||||||
Adjusted EBITDA
|
$
|
95,299
|
$
|
97,598
|
$
|
108,075
|
(a) |
Represents costs associated with corporate and CDS restructuring, including severance.
|
(b) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
|
(c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.
|
(d) |
Represents the fees incurred for transaction expenses.
|
(e) |
Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”).
|
(f) |
Represents impairment of goodwill, intangible and investment assets.
|
(g) |
Represents a federal excise tax refund included in other operating income, net.
|
(h)
|
Represents other income from litigation settlement.
|
As of
|
||||||||
(in thousands)
|
December 31,
2023
|
December 31,
2022
|
||||||
Current assets
|
$
|
149,730
|
$
|
151,251
|
||||
Current liabilities
|
100,336
|
41,376
|
||||||
Working capital
|
$
|
49,394
|
$
|
109,875
|
December 31,
2023
|
December 31,
2022
|
|||||||
Senior Secured Notes
|
$
|
250,000
|
$
|
250,000
|
||||
Convertible Senior Notes
|
118,541
|
162,500
|
||||||
Gross notes payable and long-term debt
|
368,541
|
412,500
|
||||||
Less deferred finance charges
|
(3,183
|
)
|
(5,743
|
)
|
||||
Less current maturities
|
(58,294
|
)
|
–
|
|||||
Notes payable and long-term debt
|
$
|
307,064
|
$
|
406,757
|
On or after February 15, 2023
|
102.813%
|
On or after February 15, 2024
|
101.406%
|
On or after February 15, 2025 and thereafter
|
100.000%
|
Level
|
Historical Excess Availability
|
Applicable Margin
for SOFR Loans
|
Applicable Margin
for Base Rate Loans
|
I
|
Greater than or equal to 66.66%
|
1.75%
|
0.75%
|
II
|
Less than 66.66%, but greater than or equal to 33.33%
|
2.00%
|
1.00%
|
III
|
Less than 33.33%
|
2.25%
|
1.25%
|
Sales
|
Deposits as of December 31,
|
|||||||
Year
|
2023
|
2022
|
||||||
1999
|
$
|
211
|
$
|
211
|
||||
2000
|
1,017
|
1,017
|
||||||
2001
|
1,673
|
1,673
|
||||||
2002
|
2,271
|
2,271
|
||||||
2003
|
4,249
|
4,249
|
||||||
2004
|
3,714
|
3,714
|
||||||
2005
|
4,553
|
4,553
|
||||||
2006
|
3,847
|
3,847
|
||||||
2007
|
4,167
|
4,167
|
||||||
2008
|
3,364
|
3,364
|
||||||
2009
|
1,619
|
1,619
|
||||||
2010
|
406
|
406
|
||||||
2011
|
193
|
193
|
||||||
2012
|
199
|
199
|
||||||
2013
|
173
|
173
|
||||||
2014
|
143
|
143
|
||||||
2015
|
101
|
101
|
||||||
2016
|
91
|
91
|
||||||
2017
|
82
|
82
|
||||||
Total
|
$
|
32,073
|
$
|
32,073
|
|
Page
|
|
|
Reports of RSM US LLP (PCAOB ID: )
|
59
|
Financial Statements:
|
|
62
|
|
63
|
|
Consolidated Statements of Comprehensive Income for the years ended December 31, 2023, 2022, and 2021 |
64
|
65
|
|
67
|
•
|
We evaluated the relevance and reliability of the underlying business-related data used by management by comparing it to the investees’ historical financial results.
|
•
|
We utilized valuation specialists to assist in the following procedures, among others:
|
° |
Assessing the appropriateness of management’s valuation methodologies
|
° |
Corroborating guideline public company market multiples used in the Company’s fair value calculations by comparing them to publicly available market data.
|
•
|
We evaluated the comparability of the guideline public companies identified by management to the operations of the investees.
|
•
|
We recomputed the valuation models for mathematical accuracy.
|
December 31,
|
December 31,
|
|||||||
2023
|
2022
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Accounts receivable, net of allowances of $
|
|
|
||||||
Inventories, net
|
|
|
||||||
Other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Property, plant, and equipment, net
|
|
|
||||||
Deferred income taxes |
||||||||
Right of use assets
|
|
|
||||||
Deferred financing costs, net
|
|
|
||||||
Goodwill
|
|
|
||||||
Other intangible assets, net
|
|
|
||||||
Master Settlement Agreement (MSA) escrow deposits
|
|
|
||||||
Other assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
|
$
|
|
||||
Accrued liabilities
|
|
|
||||||
Current portion of long-term debt
|
|
|
||||||
Other current liabilities
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Notes payable and long-term debt
|
|
|
||||||
Lease liabilities
|
|
|
||||||
Total liabilities
|
|
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock; $
|
|
|
||||||
Common stock, voting, $
|
|
|
||||||
Common stock, nonvoting, $
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Cost of repurchased common stock (
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Accumulated earnings
|
|
|
||||||
Non-controlling interest
|
|
|
||||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Net sales
|
$
|
|
$
|
|
$
|
|
||||||
Cost of sales
|
|
|
|
|||||||||
Gross profit
|
|
|
|
|||||||||
Selling, general, and administrative expenses
|
|
|
|
|||||||||
Other operating income, net |
( |
) | ||||||||||
Operating income
|
|
|
|
|||||||||
Interest expense, net
|
|
|
|
|||||||||
Investment loss
|
|
|
|
|||||||||
Other income |
( |
) | ||||||||||
Goodwill and intangible impairment loss | ||||||||||||
Gain on extinguishment of debt
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Income before income taxes
|
|
|
|
|||||||||
Income tax expense
|
|
|
|
|||||||||
Consolidated net income
|
|
|
|
|||||||||
Net loss attributable to non-controlling interest |
( |
) | ( |
) | ( |
) | ||||||
Net income attributable to Turning Point Brands, Inc.
|
$ | $ | $ | |||||||||
Basic income per common share:
|
||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$
|
|
||||||
Diluted income per common share:
|
||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$
|
|
||||||
Weighted average common shares outstanding:
|
||||||||||||
Basic
|
|
|
|
|||||||||
Diluted
|
|
|
|
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Consolidated net income
|
$
|
|
$
|
|
$
|
|
||||||
Other comprehensive income (loss), net of tax
|
||||||||||||
Unrealized gain (loss) on MSA investments, net of tax of $
|
|
(
|
)
|
(
|
)
|
|||||||
Foreign currency translation, net of tax of $
|
( |
) | ( |
) | ||||||||
Unrealized (loss) gain on derivative instruments, net of tax of $
|
(
|
)
|
|
|
||||||||
(
|
)
|
(
|
)
|
|
||||||||
Consolidated comprehensive income |
||||||||||||
Comprehensive loss attributable to non-controlling interest |
( |
) | ( |
) | ( |
) | ||||||
Comprehensive income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$
|
|
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Consolidated net income
|
$
|
|
$
|
|
$
|
|
||||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||||||
Gain on extinguishment of debt
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Loss (gain) on sale of property, plant, and equipment
|
( |
) | ( |
) | ||||||||
Loss on goodwill impairment
|
||||||||||||
Loss on intangible asset impairment
|
||||||||||||
Gain on insurance recovery of inventory loss
|
( |
) | ||||||||||
Loss on investments
|
|
|
|
|||||||||
Depreciation and other amortization expense
|
||||||||||||
Amortization of other intangible assets
|
|
|
|
|||||||||
Amortization of deferred financing costs
|
|
|
|
|||||||||
Deferred income tax expense (benefit)
|
|
(
|
)
|
(
|
)
|
|||||||
Stock compensation expense
|
|
|
|
|||||||||
Noncash lease income
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Gain on MSA escrow deposits
|
( |
) | ( |
) | ||||||||
Changes in operating assets and liabilities:
|
||||||||||||
Accounts receivable
|
(
|
)
|
(
|
)
|
|
|||||||
Inventories
|
|
(
|
)
|
(
|
)
|
|||||||
Other current assets
|
(
|
)
|
|
(
|
)
|
|||||||
Other assets
|
(
|
)
|
|
|
||||||||
Accounts payable
|
(
|
)
|
|
(
|
)
|
|||||||
Accrued liabilities and other
|
|
|
(
|
)
|
||||||||
Net cash provided by operating activities
|
$
|
|
$
|
|
$
|
|
||||||
Cash flows from investing activities:
|
||||||||||||
Capital expenditures
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Acquisitions, net of cash acquired
|
|
|
(
|
)
|
||||||||
Payments for investments
|
( |
) | ( |
) | ( |
) | ||||||
Restricted cash, MSA escrow deposits
|
( |
) | ( |
) | ||||||||
Proceeds on sale of property, plant and equipment
|
|
|
|
|||||||||
Net cash used in investing activities
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from Senior Notes
|
$
|
|
$
|
|
$
|
|
||||||
Payments of 2018 first lien term loan
|
|
|
(
|
)
|
||||||||
Settlement of interest rate swaps
|
|
|
(
|
)
|
||||||||
Convertible Senior Notes repurchased
|
( |
) | ( |
) | ||||||||
Proceeds from call options
|
||||||||||||
Payment of promissory note
|
( |
) | ||||||||||
Payment of dividends |
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Payments of financing costs
|
(
|
)
|
|
(
|
)
|
|||||||
Exercise of options
|
|
|
|
|||||||||
Redemption of options
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Redemption of restricted stock units
|
(
|
)
|
(
|
)
|
|
|||||||
Common stock repurchased
|
|
(
|
)
|
(
|
)
|
|||||||
Net cash (used in) provided by financing activities
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||
Net increase (decrease) in cash
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
Effect of foreign currency translation on cash
|
$ | $ | ( |
) | $ | |||||||
Cash, beginning of period:
|
||||||||||||
Unrestricted
|
$
|
|
$
|
|
$
|
|
||||||
Restricted
|
|
|
|
|||||||||
Total cash at beginning of period
|
$
|
|
$
|
|
$
|
|
||||||
Cash, end of period:
|
||||||||||||
Unrestricted
|
$
|
|
$
|
|
$
|
|
||||||
Restricted
|
|
|
|
|||||||||
Total cash at end of period
|
$
|
|
$
|
|
$
|
|
||||||
Supplemental disclosures of cash flow information:
|
||||||||||||
Cash paid during the period for interest
|
$
|
|
$
|
|
$
|
|
||||||
Cash paid during the period for income taxes, net
|
$
|
|
$
|
|
$
|
|
||||||
Supplemental schedule of noncash investing activities: |
||||||||||||
Accrued capital expenditures |
$ | $ | $ | |||||||||
Accrued consideration for acquisition of investments |
$ | $ | $ | |||||||||
Supplemental schedule of noncash financing activities:
|
||||||||||||
Dividends declared not paid
|
$
|
|
$
|
|
$
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
||||||||||||||||||||||||||||||||
Common
Stock,
Voting
|
Additional
Paid-In
Capital
|
Cost of
Repurchased
Common Stock
|
Accumulated
Earnings
(Deficit)
|
Non-
Controlling
Interest
|
||||||||||||||||||||||||||||
Voting
Shares
|
||||||||||||||||||||||||||||||||
Total
|
||||||||||||||||||||||||||||||||
Beginning balance January 1, 2021
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $
|
–
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
(
|
)
|
|||||||||||||||
Unrealized gain on derivative instruments, net of tax of $
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Foreign currency translation, net of tax of $ |
– | |||||||||||||||||||||||||||||||
Stock compensation expense
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Exercise of options
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Redemption of options
|
|
|
(
|
)
|
|
|
|
|
(
|
)
|
||||||||||||||||||||||
Cost of repurchased common stock
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Acquisition of ReCreation Marketing interest
|
– | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||
Dividends
|
– | ( |
) | ( |
) | |||||||||||||||||||||||||||
Net income
|
–
|
|
|
|
|
|
(
|
)
|
|
|||||||||||||||||||||||
Ending balance December 31, 2021
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $
|
– | $ | $ | $ | $ | ( |
) | $ | $ | $ | ( |
) | ||||||||||||||||||||
Unrealized gain on derivative instruments, net of tax of $
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Foreign currency translation, net of tax of $
|
– | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||
Stock compensation expense
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Exercise of options
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Redemption of options
|
|
|
(
|
)
|
|
|
|
|
(
|
)
|
||||||||||||||||||||||
Issuance of performance based restricted stock units | ||||||||||||||||||||||||||||||||
Redemption of performance based restricted stock units | ( |
) | ( |
) | ||||||||||||||||||||||||||||
Issuance of restricted stock units | ||||||||||||||||||||||||||||||||
Redemption of restricted stock units | ( |
) | ( |
) | ||||||||||||||||||||||||||||
Cost of repurchased common stock
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Settlement of call options, net of tax of $ |
– | |||||||||||||||||||||||||||||||
Dividends
|
–
|
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||||||
Net income
|
–
|
|
|
|
|
|
(
|
)
|
|
|||||||||||||||||||||||
Ending balance December 31, 2022
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Unrealized gain on MSA investments, net of tax of $
|
–
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||||||||||
Unrealized loss on derivative instruments, net of tax of $
|
–
|
|
|
|
(
|
)
|
|
|
(
|
)
|
||||||||||||||||||||||
Foreign currency translation, net of tax of $
|
– | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||
Stock compensation expense
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Exercise of options
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Redemption of options
|
(
|
)
|
|
(
|
)
|
|
|
|
|
(
|
)
|
|||||||||||||||||||||
Issuance of performance based restricted stock units
|
||||||||||||||||||||||||||||||||
Redemption of performance based restricted stock units
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Issuance of restricted stock units
|
||||||||||||||||||||||||||||||||
Redemption of restricted stock units
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Settlement of call options, net of tax of $
|
– |
|||||||||||||||||||||||||||||||
Dividends
|
–
|
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||||||
Net income
|
–
|
|
|
|
|
|
(
|
)
|
|
|||||||||||||||||||||||
Ending balance December 31, 2023
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
• |
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date.
|
• |
Level 2 – Inputs to the valuation methodology include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities
in inactive markets; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
|
• |
Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
|
As of December 31, 2023
|
As of December 31, 2022
|
|||||||||||||||||||||||||||||||
Gross | Gross | Estimated | Gross | Gross | Estimated | |||||||||||||||||||||||||||
Unrealized
|
Unrealized | Fair | Unrealized | Unrealized |
Fair
|
|||||||||||||||||||||||||||
Cost
|
Gains
|
Losses
|
Value
|
Cost | Gains | Losses |
Value
|
|||||||||||||||||||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
$
|
|
$
|
|
$ | $ | $ |
$
|
|
|||||||||||||||||||
U.S. Governmental agency
obligations (unrealized position < 12 months)
|
|
|
|
|
( |
) |
|
|||||||||||||||||||||||||
U.S. Governmental agency obligations (unrealized position > 12 months)
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
Total
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$ | $ | $ | ( |
) |
$
|
|
As of
|
||||
December 31, 2023
|
||||
Less than one year
|
$
|
|
||
One to five years
|
|
|||
Five to ten years
|
|
|||
Greater than ten years
|
|
|||
Total
|
$
|
|
Sales
|
Deposits as of December 31,
|
|||||||
Year
|
2023
|
2022
|
||||||
1999
|
$
|
|
$
|
|
||||
2000
|
|
|
||||||
2001
|
|
|
||||||
2002
|
|
|
||||||
2003
|
|
|
||||||
2004
|
|
|
||||||
2005
|
|
|
||||||
2006
|
|
|
||||||
2007
|
|
|
||||||
2008
|
|
|
||||||
2009
|
|
|
||||||
2010
|
|
|
||||||
2011
|
|
|
||||||
2012
|
|
|
||||||
2013
|
|
|
||||||
2014
|
|
|
||||||
2015
|
|
|
||||||
2016
|
|
|
||||||
2017
|
|
|
||||||
Total
|
$
|
|
$
|
|
December 31, | December 31, | |||||||
2023 |
2022
|
|||||||
Balance at beginning of period
|
$
|
|
$
|
|
||||
Additions to allowance account during period
|
|
|
||||||
Deductions of allowance account during period
|
(
|
)
|
(
|
)
|
||||
Balance at end of period
|
$
|
|
$
|
|
December 31,
|
December 31,
|
|||||||
2023
|
2022
|
|||||||
Raw materials and work in process
|
$
|
|
$
|
|
||||
Leaf tobacco
|
|
|
||||||
Finished goods - Zig-Zag Products
|
|
|
||||||
Finished goods - Stoker’s Products
|
|
|
||||||
Finished goods - Creative Distribution Solutions
|
|
|
||||||
Other
|
|
|
||||||
Inventories
|
$
|
|
$
|
|
2023
|
2022
|
|||||||
Balance at beginning of period
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Charged to cost and expense
|
(
|
)
|
(
|
)
|
||||
Deductions for inventory disposed
|
|
|
||||||
Balance at end of period
|
$
|
(
|
)
|
$
|
(
|
)
|
December 31, | December 31, | |||||||
2023 |
2022
|
|||||||
Inventory deposits
|
$
|
|
$
|
|
||||
Insurance deposit
|
|
|
||||||
Prepaid taxes
|
|
|
||||||
Settlement receivable |
||||||||
Insurance recovery receivable
|
||||||||
Other
|
|
|
||||||
Total
|
$
|
|
$
|
|
December 31, | December 31, | |||||||
|
2023 |
2022
|
||||||
Land
|
$
|
|
$
|
|
||||
Buildings and improvements
|
|
|
||||||
Leasehold improvements
|
|
|
||||||
Machinery and equipment
|
|
|
||||||
Furniture and fixtures
|
|
|
||||||
Gross property, plant and equipment
|
|
|
||||||
Accumulated depreciation
|
(
|
)
|
(
|
)
|
||||
Net property, plant and equipment
|
$
|
|
$
|
|
December 31, | December 31, | |||||||
|
2023 |
2022
|
||||||
Deferred financing costs, net of accumulated amortization of $
|
$
|
|
$
|
|
Zig-Zag
|
Stoker’s
|
CDS
|
Total
|
|||||||||||||
Balance as of December 31, 2021
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Impairment
|
|
|
(
|
)
|
(
|
)
|
||||||||||
Cumulative translation adjustment |
( |
) | ( |
) | ||||||||||||
Balance as of December 31, 2022
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Cumulative translation adjustment |
( |
) | ( |
) | ||||||||||||
Balance as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
$
|
|
December 31, 2023
|
December 31, 2022
|
|||||||||||||||||||||||||||||||
Zig-Zag
|
Stoker’s
|
CDS
|
Total
|
Zig-Zag
|
Stoker’s
|
CDS
|
Total
|
|||||||||||||||||||||||||
Unamortized, indefinite life intangible assets:
|
||||||||||||||||||||||||||||||||
Trade names
|
$
|
|
$
|
|
$
|
|
$
|
|
$ |
$
|
|
$
|
|
$
|
|
|||||||||||||||||
Formulas
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
$ |
$
|
|
$
|
|
$
|
|
Zig-Zag |
Stoker’s |
CDS |
||||||||||||||||||||||||||||||||||||||||||||||
December 31, 2023
|
December 31, 2022
|
December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||
Gross
|
Accumulated | Gross | Accumulated | Gross | Accumulated |
Gross | Accumulated | Gross | Accumulated | Gross | Accumulated |
|||||||||||||||||||||||||||||||||||||
Carrying
|
Amortization
|
Carrying
|
Amortization
|
Carrying |
Amortization |
Carrying |
Amortization | Carrying |
Amortization |
Carrying | Amortization | |||||||||||||||||||||||||||||||||||||
Amortized intangible assets:
|
||||||||||||||||||||||||||||||||||||||||||||||||
Customer relationships (useful life of
|
$
|
|
$
|
|
$
|
|
$
|
|
$ |
$ |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||||||||||||||||
Trade names (useful life of
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Formulas (useful life of
|
||||||||||||||||||||||||||||||||||||||||||||||||
Master distribution agreement (useful life of
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Franchise agreements (useful life of
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Non-compete agreements (useful life of
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
$ | $ | $ | $ | $ | $ | $ | $ |
December 31, | December 31, | |||||||
2023 |
2022
|
|||||||
Equity investments
|
$
|
|
$
|
|
||||
Debt security investment
|
|
|
||||||
Capitalized software
|
||||||||
Other
|
|
|
||||||
Total
|
$
|
|
$
|
|
December 31,
|
December 31,
|
|||||||
|
2023 |
2022
|
||||||
Accrued payroll and related items
|
$
|
|
$
|
|
||||
Customer returns and allowances
|
|
|
||||||
Taxes payable
|
|
|
||||||
Lease liabilities
|
|
|
||||||
Accrued interest
|
|
|
||||||
Other
|
|
|
||||||
Total
|
$
|
|
$
|
|
December 31,
|
December 31,
|
|||||||
2023 |
2022
|
|||||||
Senior Secured Notes |
$ | $ | ||||||
Convertible Senior Notes
|
|
|
||||||
Gross notes payable and long-term debt
|
|
|
||||||
Less deferred finance charges
|
(
|
)
|
(
|
)
|
||||
Less current maturities
|
( |
) | ||||||
Notes payable and long-term debt
|
$
|
|
$
|
|
On or after February 15, 2023
|
|
%
|
||
On or after February 15, 2024
|
|
%
|
||
On or after February 15, 2025 and thereafter
|
|
%
|
Level
|
Historical Excess Availability
|
Applicable Margin for
SOFR Loans
|
Applicable Margin for
Base Rate Loans
|
I
|
Greater than or equal to
|
|
|
II
|
Less than
|
|
|
III
|
Less than
|
|
|
2023
|
2022
|
2021
|
||||||||||||||||||||||||||||||||||
Current
|
Deferred
|
Total
|
Current
|
Deferred
|
Total
|
Current
|
Deferred
|
Total
|
||||||||||||||||||||||||||||
Federal
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||||||||||
State and Local
|
|
|
|
|
(
|
)
|
|
|
(
|
)
|
|
|||||||||||||||||||||||||
Foreign |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
December 31, | December 31, | |||||||||||||||
2023 |
2022
|
|||||||||||||||
Assets
|
Liabilities
|
Assets
|
Liabilities
|
|||||||||||||
Inventory
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Property, plant, and equipment
|
|
|
|
|
||||||||||||
Goodwill and other intangible assets
|
|
|
|
|
||||||||||||
Foreign NOL carryforward
|
|
–
|
|
–
|
||||||||||||
State NOL carryforward
|
|
–
|
|
–
|
||||||||||||
Unrealized loss on investments
|
|
–
|
|
–
|
||||||||||||
Leases
|
|
|
|
|
||||||||||||
Original issue discount
|
|
|
|
|
||||||||||||
Stock compensation | – | – | ||||||||||||||
Insurance receivable | – | – | ||||||||||||||
Other
|
|
|
|
|
||||||||||||
Gross deferred income taxes
|
|
|
|
|
||||||||||||
Valuation allowance
|
(
|
)
|
–
|
(
|
)
|
–
|
||||||||||
Net deferred income taxes
|
$
|
|
$
|
|
$
|
|
$
|
|
2023
|
2022
|
2021
|
||||||||||
Federal statutory rate
|
|
%
|
|
%
|
|
%
|
||||||
Foreign rate differential |
( |
)% | ( |
)% | ( |
)% | ||||||
State taxes
|
|
%
|
|
%
|
|
%
|
||||||
Permanent differences
|
(
|
)%
|
(
|
)%
|
(
|
)%
|
||||||
Other
|
|
|
%
|
|
%
|
|||||||
Valuation allowance
|
|
%
|
|
%
|
|
%
|
||||||
Effective income tax rate
|
|
%
|
|
%
|
|
%
|
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021 |
||||||||||
Operating lease cost
|
||||||||||||
Cost of sales
|
$
|
|
$
|
|
$ | |||||||
Selling, general and administrative
|
|
|
||||||||||
Variable lease cost (1)
|
|
|
||||||||||
Short-term lease cost
|
|
|
||||||||||
Sublease income
|
|
|
( |
) | ||||||||
Total
|
$
|
|
$
|
|
$ |
(1) |
|
For the year ended December 31, | ||||||||||||
|
2023
|
2022
|
2021
|
|||||||||
Financing lease cost
|
||||||||||||
Selling, general and administrative
|
$
|
|
$
|
|
$
|
|
||||||
Total
|
$
|
|
$
|
|
$
|
|
December 31,
|
December 31,
|
|||||||
|
2023 |
2022
|
||||||
Assets:
|
||||||||
|
$
|
|
$
|
|
||||
|
|
|||||||
Total lease assets
|
$
|
|
$
|
|
||||
Liabilities:
|
||||||||
- Operating (2) |
$
|
|
$
|
|
||||
|
|
|
||||||
Total lease liabilities
|
$
|
|
$
|
|
(2) |
|
December 31,
|
December 31,
|
|||||||
2023
|
2022
|
|||||||
Right of use assets obtained in exchange for lease obligations:
|
||||||||
Operating leases
|
$
|
|
$
|
|
||||
Finance leases
|
$
|
|
$
|
|
As of December 31,
|
||||||||
2023
|
2022
|
|||||||
Weighted-average remaining lease term - operating leases
|
|
|
||||||
Weighted-average discount rate - operating leases
|
|
%
|
|
%
|
||||
Weighted-average remaining lease term - financing leases |
||||||||
Weighted-average discount rate - financing leases |
% | % |
Year |
Operating
|
Finance
|
||||||
2024
|
$
|
|
$
|
|
||||
2025
|
|
|
||||||
2026
|
|
|
||||||
2027
|
|
|
||||||
2028
|
|
|
||||||
Years thereafter
|
|
|
||||||
Total lease payments
|
|
|
|
|
||||
Less: Imputed interest
|
|
|
||||||
Present value of lease liabilities
|
$
|
|
$
|
|
Weighted | Weighted | |||||||||||
Stock | Average | Average | ||||||||||
Option | Exercise |
Grant Date
|
||||||||||
Shares
|
Price
|
Fair Value
|
||||||||||
Outstanding, December 31, 2021
|
|
$ |
|
$ |
|
|||||||
Granted
|
|
|
|
|||||||||
Exercised
|
(
|
)
|
|
|
||||||||
Forfeited
|
(
|
)
|
|
|
||||||||
Outstanding, December 31, 2022
|
|
$
|
|
$
|
|
|||||||
Granted
|
|
|
|
|||||||||
Exercised
|
(
|
)
|
|
|
||||||||
Forfeited
|
(
|
)
|
|
|
||||||||
Outstanding, December 31, 2023
|
|
$
|
|
$
|
|
February 10, | May 17, |
March 7,
|
March 20,
|
October 24, |
March 18,
|
February 18,
|
May 3,
|
|||||||||||||||||||||||||
2017
|
2017
|
2018
|
2019
|
2019
|
2020
|
2021
|
2021
|
|||||||||||||||||||||||||
Number of options granted
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Options outstanding at December 31, 2023
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Number exercisable at December 31, 2023
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Exercise price
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$ | $ | ||||||||||||||||||
Remaining lives
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Risk free interest rate
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
% | % | ||||||||||||||||||
Expected volatility
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
% | % | ||||||||||||||||||
Expected life
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Dividend yield
|
|
|
|
%
|
|
%
|
|
%
|
|
%
|
% | % | ||||||||||||||||||||
Fair value at grant date
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$ | $ |
May 17,
|
March 14,
|
April 29,
|
May 12,
|
|||||||||||||
2021
|
2022
|
2022
|
2023
|
|||||||||||||
Number of options granted
|
|
|
|
|
||||||||||||
Options outstanding at December 31, 2023
|
|
|
|
|
||||||||||||
Number exercisable at December 31, 2023
|
|
|
|
|
||||||||||||
Exercise price
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Remaining lives
|
|
|
|
|
||||||||||||
Risk free interest rate
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||
Expected volatility
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||
Expected life
|
|
|
|
|
||||||||||||
Dividend yield
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||
Fair value at grant date
|
$
|
|
$
|
|
$
|
|
$
|
|
March 20,
|
March 18,
|
December 28,
|
February 18,
|
March 14,
|
May 4,
|
|||||||||||||||||||
2019
|
2020
|
2020
|
2021
|
2022
|
2023
|
|||||||||||||||||||
Number of PRSUs granted
|
|
|
|
|
|
|
||||||||||||||||||
PRSUs outstanding at December 31, 2023
|
|
|
|
|
|
|
||||||||||||||||||
Fair value as of grant date
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Remaining lives
|
–
|
|
–
|
|
|
|
March 14,
|
March 14,
|
April 29,
|
May 5,
|
May 5,
|
May 8,
|
|||||||||||||||||||
2022
|
2022
|
2022
|
2023
|
2023
|
2023
|
|||||||||||||||||||
Number of RSUs granted
|
|
|
|
|
|
|
||||||||||||||||||
RSUs outstanding at December 31, 2023
|
|
|
|
|
|
|
||||||||||||||||||
Fair value as of grant date
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Remaining lives
|
|
|
|
|
–
|
|
December 31, 2023 |
December 31, 2022 |
December 31, 2021 |
||||||||||||||||||||||||||||||||||
Per | Per | Per |
||||||||||||||||||||||||||||||||||
Income
|
Shares
|
Share
|
Income
|
Shares
|
Share
|
Income
|
Shares
|
Share
|
||||||||||||||||||||||||||||
Basic EPS:
|
||||||||||||||||||||||||||||||||||||
Numerator
|
||||||||||||||||||||||||||||||||||||
Net income attributable to Turning
Point Brands, Inc.
|
$
|
|
$
|
|
$
|
|
||||||||||||||||||||||||||||||
Denominator
|
||||||||||||||||||||||||||||||||||||
Weighted average
|
|
$
|
|
|
$
|
|
|
$
|
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Diluted EPS:
|
||||||||||||||||||||||||||||||||||||
Numerator
|
||||||||||||||||||||||||||||||||||||
Net income attributable to Turning
Point Brands, Inc.
|
$
|
|
$
|
|
$
|
|
||||||||||||||||||||||||||||||
Interest expense related to
Convertible Senior Notes, net of
tax
|
|
|
|
|||||||||||||||||||||||||||||||||
Diluted consolidated net income
|
$
|
|
$
|
|
$
|
|
||||||||||||||||||||||||||||||
Denominator
|
||||||||||||||||||||||||||||||||||||
Basic weighted average
|
|
|
|
|||||||||||||||||||||||||||||||||
Convertible Senior Notes (1)
|
|
|
|
|||||||||||||||||||||||||||||||||
Stock options and restricted stock units
|
|
|
|
|||||||||||||||||||||||||||||||||
|
$
|
|
|
$
|
|
|
$
|
|
(1) |
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Net sales
|
||||||||||||
Zig-Zag products
|
$
|
|
$
|
|
$
|
|
||||||
Stoker’s products
|
|
|
|
|||||||||
Total Zig-Zag and Stoker’s products
|
|
|
|
|||||||||
Creative Distribution Solutions
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
||||||
Gross profit
|
||||||||||||
Zig-Zag products
|
$
|
|
$
|
|
$
|
|
||||||
Stoker’s products
|
|
|
|
|||||||||
Total Zig-Zag and Stoker’s products
|
||||||||||||
Creative Distribution Solutions
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
||||||
Operating income (loss)
|
||||||||||||
Zig-Zag products
|
$
|
|
$
|
|
$
|
|
||||||
Stoker’s products
|
|
|
|
|||||||||
Corporate unallocated (1)(2)
|
( |
) | ( |
) | ( |
) | ||||||
Total Zig-Zag and Stoker’s products
|
||||||||||||
Creative Distribution Solutions
|
( |
) | ||||||||||
Total
|
$
|
|
$
|
|
$
|
|
||||||
Interest expense, net
|
|
|
|
|||||||||
Investment loss
|
|
|
|
|||||||||
Other income
|
( |
) | ||||||||||
Goodwill and intangible impairment loss
|
||||||||||||
Gain on extinguishment of debt
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Income before income taxes
|
$
|
|
$
|
|
$
|
|
||||||
Capital expenditures
|
||||||||||||
Zig-Zag products
|
$
|
|
$
|
|
$
|
|
||||||
Stoker’s products
|
|
|
|
|||||||||
Total Zig-Zag and Stoker’s products | ||||||||||||
Creative Distribution Solutions
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
||||||
Depreciation and amortization
|
||||||||||||
Zig-Zag products
|
$
|
|
$
|
|
$
|
|
||||||
Stoker’s products
|
|
|
|
|||||||||
Total Zig-Zag and Stoker’s products
|
||||||||||||
Creative Distribution Solutions
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
(1) |
|
(2) |
|
December 31, |
December 31,
|
|||||||
2023 |
2022
|
|||||||
Assets
|
||||||||
Zig-Zag products
|
$
|
|
$
|
|
||||
Stoker’s products
|
|
|
||||||
Corporate unallocated (1)
|
|
|
||||||
Total Zig-Zag and Stoker’s products | ||||||||
Creative Distribution Solutions
|
||||||||
Total
|
$
|
|
$
|
|
(1) |
|
Creative Distribution Solutions
|
||||||||||||
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Business to Business
|
$
|
|
$
|
|
$
|
|
||||||
Business to Consumer - Online
|
|
|
|
|||||||||
Other
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
For the year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Domestic
|
$
|
|
$
|
|
$
|
|
||||||
Foreign
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
1st
|
2nd
|
3rd
|
4th
|
|||||||||||||
2023
|
||||||||||||||||
Net sales
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Gross profit
|
|
|
|
|
||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
|
|
|
|
||||||||||||
Basic net income attributable to Turning Point Brands, Inc. per share
|
|
|
|
|
||||||||||||
Diluted net income attributable to Turning Point Brands, Inc. per share
|
$
|
|
$
|
|
$
|
|
$
|
|
|
|||||||
2022
|
||||||||||||||||
Net sales
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Gross profit
|
|
|
|
|
||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
|
|
|
(
|
)
|
|||||||||||
Basic net income attributable to Turning Point Brands, Inc. per share
|
|
|
|
(
|
)
|
|||||||||||
Diluted net income attributable to Turning Point Brands, Inc. per share
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)(1)
|
(1) |
|
Years Ended December 31,
|
||||||||||||||||||||||||
2023
|
2022
|
|||||||||||||||||||||||
Company and
Restricted
Subsidiaries
|
Unrestricted
Subsidiaries
|
Consolidated
|
Company and
Restricted
Subsidiaries
|
Unrestricted
Subsidiaries
|
Consolidated
|
|||||||||||||||||||
Net sales
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Cost of sales
|
|
|
|
|
|
|
||||||||||||||||||
Gross profit
|
|
|
|
|
|
|
||||||||||||||||||
Selling, general, and administrative expenses
|
|
|
|
|
|
|
||||||||||||||||||
Other operating income, net
|
(
|
)
|
|
(
|
)
|
|
|
|
||||||||||||||||
Operating income (loss)
|
|
(
|
)
|
|
|
|
|
|||||||||||||||||
Interest expense, net
|
|
|
|
|
|
|
||||||||||||||||||
Investment loss
|
|
|
|
|
|
|
||||||||||||||||||
Other income
|
(
|
)
|
|
(
|
)
|
|
|
|
||||||||||||||||
Goodwill and intangible impairment loss
|
|
|
|
|
|
|||||||||||||||||||
Gain on extinguishment of debt
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|
(
|
)
|
||||||||||||||
Income (loss) before income taxes
|
|
(
|
)
|
|
|
|
|
|||||||||||||||||
Income tax expense
|
|
(
|
)
|
|
|
|
|
|||||||||||||||||
Consolidated net income (loss)
|
|
(
|
)
|
|
|
|
|
|||||||||||||||||
Net loss attributable to non-controlling interest
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|
(
|
)
|
||||||||||||||
Net income (loss) attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
$
|
|
Year Ended December 31, | ||||||||||||
2021
|
||||||||||||
Company and
Restricted
Subsidiaries
|
Unrestricted
Subsidiaries
|
Consolidated
|
||||||||||
Net sales
|
$
|
|
$
|
|
$
|
|
||||||
Cost of sales
|
|
|
|
|||||||||
Gross profit
|
|
|
|
|||||||||
Selling, general, and administrative expenses
|
|
|
|
|||||||||
Operating income
|
|
|
||||||||||
Interest expense, net
|
|
|
|
|||||||||
Investment loss
|
|
|
|
|||||||||
Gain on extinguishment of debt
|
(
|
)
|
|
(
|
)
|
|||||||
Income before income taxes
|
|
|
|
|||||||||
Income tax expense
|
|
|
|
|||||||||
Consolidated net income
|
|
|
|
|||||||||
Net loss attributable to non-controlling interest
|
(
|
)
|
|
(
|
)
|
|||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$
|
|
ASSETS
|
Company and
Restricted
Subsidiaries
|
Unrestricted
Subsidiaries
|
Eliminations
|
Consolidated
|
||||||||||||
Current assets:
|
||||||||||||||||
Cash
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Accounts receivable, net
|
|
|
|
|
||||||||||||
Inventories, net
|
|
|
|
|
||||||||||||
Other current assets
|
|
|
|
|
||||||||||||
Total current assets
|
|
|
|
|
||||||||||||
Property, plant, and equipment, net
|
|
|
|
|
||||||||||||
Deferred income taxes
|
|
|
|
|
||||||||||||
Right of use assets
|
|
|
|
|
||||||||||||
Deferred financing costs, net
|
|
|
|
|
||||||||||||
Goodwill
|
|
|
|
|
||||||||||||
Other intangible assets, net
|
|
|
|
|
||||||||||||
Master Settlement Agreement (MSA) escrow deposits
|
|
|
|
|
||||||||||||
Other assets
|
|
|
|
|
||||||||||||
Investment in unrestricted subsidiaries
|
|
|
(
|
)
|
|
|||||||||||
Total assets
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||||||||||
Current liabilities:
|
||||||||||||||||
Accounts payable
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Accrued liabilities
|
|
|
|
|
||||||||||||
Current portion of long-term debt
|
|
|
|
|
||||||||||||
Total current liabilities
|
|
|
|
|
||||||||||||
Notes payable and long-term debt
|
|
|
|
|
||||||||||||
Lease liabilities
|
|
|
|
|
||||||||||||
Total liabilities
|
|
|
|
|
||||||||||||
Commitments and contingencies
|
||||||||||||||||
Stockholders’ equity:
|
||||||||||||||||
Total Turning Point Brands Inc. Stockholders’ Equity/Net parent investment in unrestricted subsidiaries
|
|
|
(
|
)
|
|
|||||||||||
Non-controlling interest
|
|
|
|
|
||||||||||||
Total stockholders’ equity
|
|
|
(
|
)
|
|
|||||||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
ASSETS
|
Company and
Restricted
Subsidiaries
|
Unrestricted
Subsidiaries
|
Eliminations
|
Consolidated
|
||||||||||||
Current assets:
|
||||||||||||||||
Cash
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Accounts receivable, net
|
|
|
|
|
||||||||||||
Inventories, net
|
|
|
|
|
||||||||||||
Other current assets
|
|
|
|
|
||||||||||||
Total current assets
|
|
|
|
|
||||||||||||
Property, plant, and equipment, net
|
|
|
|
|
||||||||||||
Deferred income taxes
|
|
|
|
|
||||||||||||
Right of use assets
|
|
|
|
|
||||||||||||
Deferred financing costs, net
|
|
|
|
|
||||||||||||
Goodwill
|
|
|
|
|
||||||||||||
Other intangible assets, net
|
|
|
|
|
||||||||||||
Master Settlement Agreement (MSA) escrow deposits
|
|
|
|
|
||||||||||||
Other assets
|
|
|
|
|
||||||||||||
Investment in unrestricted subsidiaries
|
|
|
(
|
)
|
|
|||||||||||
Total assets
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||||||||||
Current liabilities:
|
||||||||||||||||
Accounts payable
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Accrued liabilities
|
|
|
|
|
||||||||||||
Other current liabilities
|
|
|
|
|
||||||||||||
Total current liabilities
|
|
|
|
|
||||||||||||
Notes payable and long-term debt
|
|
|
|
|
||||||||||||
Lease liabilities
|
|
|
|
|
||||||||||||
Total liabilities
|
|
|
|
|
||||||||||||
Commitments and contingencies
|
||||||||||||||||
Stockholders’ equity:
|
||||||||||||||||
Total Turning Point Brands Inc. Stockholders’ Equity/Net parent investment in unrestricted subsidiaries
|
|
|
(
|
)
|
|
|||||||||||
Non-controlling interest
|
|
|
|
|
||||||||||||
Total stockholders’ equity
|
|
|
(
|
)
|
|
|||||||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|
a) |
Financial Information
|
(1) |
Financial Statements: See “Index to Consolidated Financial Statements” in Part II, Item 8 of this Annual Report on Form 10-K.
|
(2) |
Financial Statement Schedule: Information required by this item is included within the consolidated financial statements or notes in Item 8 of this Annual Report on Form 10-K.
|
(3) |
Exhibits – See (b) below
|
b) | Exhibits Index to Exhibits |
Exhibit No.
|
Description
|
International Vapor Group Stock Purchase Agreement dated as of September 5, 2018, between Turning Point Brands, Inc. and International Vapor
Group, LLC (incorporated by reference to Exhibit 2.1 to the Registrant’s Quarterly Report on Form 10-Q filed on November 7, 2018).
|
|
|
|
Second Amended and Restated Certificate of Incorporation of Turning Point Brands, Inc. (incorporated by reference to Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K filed on May 16, 2016).
|
|
|
|
Second Amended and Restated By-laws (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on
October 27, 2020).
|
|
|
|
Registration Rights Agreement of Turning Point Brands, Inc. dated May 10, 2016, between Turning Point Brands, Inc. and the Stockholders named
therein (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on May 16, 2016).
|
|
|
|
Description of Securities. (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed on March 12,
2020).
|
|
|
|
Indenture dated as of July 30, 2019, between Turning Point Brands, Inc. and GLAS Trust Company LLC (including the form of Note as Exhibit A
thereto) (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on July 31, 2019).
|
|
Indenture dated as of February 11, 2021, between Turning Point Brands, Inc. and GLAS Trust Company LLC, (including the form of Note as
Exhibit A thereto) (incorporated by reference to Exhibit 4.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 5, 2021).
|
|
Turning Point Brands, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) dated as of March 22, 2021. †
|
|
|
|
Turning Point Brands, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) (incorporated by reference to Exhibit 10.1 to the Registrant’s
Registration Statement on Form S-1/A (File No. 333-207816) filed on November 5, 2015). †
|
|
|
|
Form of Stock Option Award Agreement under the 2015 Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form
10-K filed on March 13, 2017). †
|
|
|
|
Form of Performance-Based Restricted Stock Unit Award Agreement under the Turning Point Brands, Inc. 2015 Equity Incentive Plan (incorporated
by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed on May 11, 2017). †
|
2006 Equity Incentive Plan of Turning Point Brands, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration
Statement on Form S-1/A (File No. 333-207816) filed on November 5, 2015). †
|
|
|
|
Amendment No. 1 to the 2006 Equity Incentive Plan of North Atlantic Holding Company, Inc. (incorporated by reference to Exhibit 10.4 to the
Registrant’s Annual Report on Form 10-K filed on March 13, 2017). †
|
|
|
|
Amendment No. 2 to the 2006 Equity Incentive Plan of North Atlantic Holding Company, Inc. (incorporated by reference to Exhibit 10.5 to the
Registrant’s Annual Report on Form 10-K filed on March 13, 2017). †
|
|
|
|
Amendment No. 3 to the 2006 Equity Incentive Plan of North Atlantic Holding Company, Inc. (incorporated by reference to Exhibit 10.1 to the
Registrant’s Current Report on Form 8-K filed on February 7, 2017). †
|
|
|
|
Amendment No. 4 to the 2006 Equity Incentive Plan of North Atlantic Holding Company, Inc. (incorporated by reference to Exhibit 10.54 to the
Registrant’s Annual Report on Form 10-K filed on March 13, 2017). †
|
|
Form of Award Agreement under the 2006 Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form
S-1/A (File No. 333-207816) filed on November 5, 2015). †
|
|
|
|
Form of Cash-Out Agreement under the 2006 Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K
filed on February 7, 2017). †
|
|
|
|
Form of Indemnification Agreement between Turning Point Brands, Inc. and certain directors and officers (incorporated by reference to Exhibit
10.10 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-207816) filed on November 24, 2015).
|
|
|
|
Contract Manufacturing, Packaging and Distribution Agreement dated as of September 4, 2008, between National Tobacco Company, L.P. and
Swedish Match North America, Inc. (incorporated by reference to Exhibit 10.17 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-207816) filed on November 24, 2015).
|
|
|
|
Amended and Restated Distribution and License Agreement dated as of November 30, 1992, between Bolloré Technologies, S.A. and North Atlantic
Trading Company, Inc., as predecessor to North Atlantic Operating Company, Inc. (U.S.) (incorporated by reference to Exhibit 10.2 to Amendment No. 2 to the Registrant’s Registration Statement (Reg. No. 333-31931) on Form S-4/A filed
with the Commission on September 17, 1997).
|
|
|
|
Amended and Restated Distribution and License Agreement dated as of November 30, 1992, between Bolloré Technologies, S.A. and North Atlantic
Trading Company, Inc., as predecessor to North Atlantic Operating Company, Inc. (Canada) (incorporated by reference to Exhibit 10.4 to Amendment No. 2 to the Registrant’s Registration Statement (Reg. No. 333-31931) on Form S-4/A filed
with the Commission on September 17, 1997).
|
|
|
|
Amendment to the Amended and Restated Distribution and License Agreement dated March 31, 1993 between Bolloré Technologies, S.A. and North
Atlantic Trading Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.22 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Amendment to the Amended and Restated Distribution and License Agreements dated June 10, 1996, between Bolloré Technologies, S.A. and North
Atlantic Trading Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.23 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Amendment to the Amended and Restated Distribution and License Agreement dated September 1996, between Bolloré Technologies, S.A. and North
Atlantic Trading Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.24 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Restated Amendment to the Amended and Restated Distribution and License Agreement between Bolloré Technologies, S.A. and North Atlantic
Operating Company, Inc. dated June 25, 1997 (U.S. & Canada) (incorporated by reference to Exhibit 10.5 to Amendment No. 2 to the Registrant’s Registration Statement (Reg. No. 333-31931) on Form S-4/A filed with the Commission on
September 17, 1997).
|
|
|
|
Amendment to the Amended and Restated Distribution and License Agreement dated October 22, 1997, between Bolloré Technologies, S.A. and North
Atlantic Operating Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.31 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).
|
Amendment to the Amended and Restated Distribution and License Agreement dated June 19, 2002, between Bolloré S.A. and North Atlantic
Operating Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.31 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Trademark Consent Agreement, dated March 26, 1997, between Bolloré Technologies, S.A. and North Atlantic Trading Company, Inc. (incorporated
by reference to Exhibit 10.25 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Amendment to the Amended and Restated Distribution and License Agreement dated February 28, 2005, between Bolloré S.A. and North Atlantic
Operating Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.33 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
Amendment to the Amended and Restated Distribution and License Agreement dated April 20, 2006, between Bolloré S.A. and North Atlantic
Operating Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006).
|
|
|
|
Amendment to the Amended and Restated Distribution and License Agreement dated March 10, 2010, between Bolloré S.A. and North Atlantic
Operating Company, Inc. (U.S. & Canada) (incorporated by reference to Exhibit 10.35 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Consent Agreement dated as of April 4, 1997, between Bolloré Technologies, S.A. and North Atlantic Trading Company, Inc. (incorporated by
reference to Exhibit 10.26 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Amendment No. 1 to Consent Agreement dated as of April 9, 1997, between Bolloré Technologies, S.A. and North Atlantic Operating Company, Inc.
(incorporated by reference to Exhibit 10.27 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Amendment No. 2 to Consent Agreement dated as of June 25, 1997, between Bolloré Technologies, S.A. and North Atlantic Operating Company, Inc.
(incorporated by reference to Exhibit 10.28 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Trademark Consent Agreement dated July 31, 2003, among Bolloré Technologies, S.A., North Atlantic Trading Company, Inc. and North Atlantic
Operating Company, Inc. (incorporated by reference to Exhibit 10.32 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Amendment No. 2 to Trademark Consent Agreement dated December 17, 2012, between Bolloré S.A. and North Atlantic Operating Company, Inc.
(incorporated by reference to Exhibit 10.36 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
License and Distribution Agreement dated March 19, 2013 between Bolloré S.A. and North Atlantic Operating Company, Inc. (incorporated by
reference to Exhibit 10.37 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207816) filed on November 5, 2015).
|
|
|
|
Distributors Supply Agreement dated as of April 1, 2013, between National Tobacco Company, L.P. and JJA Distributors, LLC (incorporated by
reference to Exhibit 10.38 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-207816) filed on November 24, 2015).
|
|
Form of Capped Call Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 31, 2019).
|
|
|
|
Employment Agreement by and between the Company and David Glazek, dated as of November 2, 2022. †
|
|
Employment Agreement by and between the Company and Graham A. Purdy, dated as of January 30, 2023. †
|
|
|
|
Employment Agreement by and between the Company and Luis Reformina, dated as of March 23, 2021 (incorporated by reference to Exhibit 10.1 to
the Registrant’s Current Report on Form 8-K filed on March 24, 2021) †
|
ABL Credit Agreement dated as of November 7, 2023, between TPB Specialty Finance LLC, as the borrower, the lenders and L/C issuers party thereto, Barclays Bank PLC, as administrative
agent and collateral agent, and First-Citizens Bank & Trust Company, as additional collateral agent and Barclays Bank PLC and First-Citizens Bank & Trust Company as joint lead arrangers and joint bookrunners. *
|
|
Pledge and Security Agreement dated as of November 7, 2023 by and among TPB Specialty Finance LLC, as the grantor, and Barclays Bank PLC, in its capacity as
collateral agent for the Lenders and L/C Issuers, Barclays Bank PLC, as administrative agent and collateral agent, and First-Citizens Bank & Trust Company. *
|
|
Subsidiaries of Turning Point Brands, Inc.*
|
|
Consent of RSM US LLP.*
|
|
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
|
|
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
|
|
Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
|
|
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
|
|
Clawback policy of Turning Point Brands, Inc. *
|
|
101
|
XBRL (eXtensible Business Reporting Language). The following materials from Turning Point Brands, Inc.’s Annual Report on Form 10-K for the years ended December 31, 2023, 2022, and
2021, formatted in Inline XBRL: (i) consolidated balance sheets, (ii) consolidated statements of income, (iii) consolidated statements of comprehensive income, (iv) consolidated statements of changes in stockholder’s equity (deficit), (v)
consolidated statements of cash flows, and (vi) notes to the consolidated financial statements.*
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).*
|
* |
Filed herewith
|
† |
Compensatory plan or arrangement
|
TURNING POINT BRANDS, INC.
|
|||
By:
|
/s/ Graham Purdy
|
||
Name: Graham Purdy
|
|||
Title: Chief Executive Officer
|
|||
By:
|
/s/ Luis Reformina
|
||
Name: Luis Reformina
|
|||
Title: Chief Financial Officer
|
|||
By:
|
/s/ Brian Wigginton
|
||
Name: Brian Wigginton
|
|||
Title: Chief Accounting Officer
|
Signature
|
Title
|
Date
|
|||
By:
|
/s/ Graham Purdy
|
Director, Chief Executive Officer
|
February 28, 2024
|
||
Graham Purdy
|
|||||
By:
|
/s/ Luis Reformina
|
Chief Financial Officer
|
February 28, 2024
|
||
Luis Reformina
|
|||||
By:
|
/s/ Brian Wigginton
|
Chief Accounting Officer
|
February 28, 2024
|
||
Brian Wigginton
|
|||||
By:
|
/s/ David Glazek
|
Executive Chair of the Board
|
February 28, 2024
|
||
David Glazek
|
|||||
By:
|
/s/ Gregory H. A. Baxter
|
Director
|
February 28, 2024
|
||
Gregory H. A. Baxter
|
|||||
By:
|
/s/ H. C. Charles Diao
|
Director
|
February 28, 2024
|
||
H. C. Charles Diao
|
|||||
By:
|
/s/ Rohith Reddy
|
Director
|
February 28, 2024
|
||
Rohith Reddy
|
|||||
By:
|
/s/ Arnold Zimmerman
|
Director
|
February 28, 2024
|
||
Arnold Zimmerman
|
|||||
By:
|
/s/ Ashley Davis Frushone
|
Director
|
February 28, 2024
|
||
Ashley Davis Frushone
|
|||||
By:
|
/s/ Stephen Usher
|
Director
|
February 28, 2024
|
||
Stephen Usher
|
|||||
By:
|
/s/ Lawrence S. Wexler
|
Director
|
February 28, 2024
|
||
Lawrence S. Wexler
|